156 related articles for article (PubMed ID: 2190398)
21. Cyclophilin binding: a receptor-mediated approach to monitoring cyclosporine immunosuppressive activity following organ transplantation.
Lorber MI; Paul K; Harding MW; Handschumacher RE; Marks WH
Transplant Proc; 1990 Jun; 22(3):1240-4. PubMed ID: 2190386
[No Abstract] [Full Text] [Related]
22. Adjustment of cyclosporine dosage in renal transplant patients based on concentration measured specifically in whole blood: clinical outcome results and diagnostic utility.
Shaw LM; Audet PR; Grossman RA; Fields L; Lensmeyer GL; Dafoe DC
Transplant Proc; 1990 Jun; 22(3):1267-73. PubMed ID: 2349688
[No Abstract] [Full Text] [Related]
23. Value of cyclosporine measurements in renal transplant recipients immunosuppressed with triple therapy.
Taube D; Marsden J; Palmer A; Cairns T; Johnston A; Holt DW
Transplant Proc; 1990 Jun; 22(3):1251-2. PubMed ID: 2349686
[No Abstract] [Full Text] [Related]
24. A monoclonal antibody fluorescent polarization immunoassay for cyclosporine.
Wang P; Meucci V; Simpson E; Morrison M; Lunetta S; Zajac M; Boeckx R
Transplant Proc; 1990 Jun; 22(3):1186-8. PubMed ID: 2190379
[No Abstract] [Full Text] [Related]
25. Two immunosuppressive drug regimens after renal transplantation: low dosage of cyclosporine adjusted on the basis of high-performance liquid chromatography whole blood levels and prednisone.
Uchida K; Orihara A; Yamada N; Tominaga Y; Kawai M; Tanaka Y; Morozumi K; Hayashi S; Satake M; Taira N
Transplant Proc; 1988 Feb; 20(1 Suppl 1):401-5. PubMed ID: 3279629
[No Abstract] [Full Text] [Related]
26. Cyclosporine monitoring with polyclonal and specific monoclonal antibodies during episodes of renal allograft dysfunction.
Holt DW; Marsden JT; Johnston A; Taube DH
Transplant Proc; 1989 Feb; 21(1 Pt 2):1482-4. PubMed ID: 2652475
[No Abstract] [Full Text] [Related]
27. Cyclosporine and metabolites in blood from renal allograft recipients with nephrotoxicity, rejection, or good renal function: comparative high-performance liquid chromatography and monoclonal radioimmunoassay studies.
Rosano TG; Pell MA; Freed BM; Dybas MT; Lempert N
Transplant Proc; 1988 Apr; 20(2 Suppl 2):330-8. PubMed ID: 3284076
[No Abstract] [Full Text] [Related]
28. Influence of different parameters for the monitoring of cyclosporine.
Humbert H; Vernillet L; Cabiac MD; Barradas J; Billaud E
Transplant Proc; 1990 Jun; 22(3):1210-5. PubMed ID: 2349682
[No Abstract] [Full Text] [Related]
29. [The significance and problem of cyclosporine blood level monitoring].
Yuhki Y
Rinsho Byori; 1990 Feb; 38(2):157-62. PubMed ID: 2184276
[TBL] [Abstract][Full Text] [Related]
30. Cyclosporine--high-dose steroid interaction in renal transplant recipients: assessment by HPLC.
Ptachcinski RJ; Venkataramanan R; Burckart GJ; Hakala TR; Rosenthal JT; Carpenter BJ; Taylor RJ
Transplant Proc; 1987 Feb; 19(1 Pt 2):1728-9. PubMed ID: 3274417
[No Abstract] [Full Text] [Related]
31. [The diagnosis of cyclosporin nephrotoxicity in patients after kidney transplantation].
Rozental' RL; Il'inskiĭ IM; Bitsans IaB; Strokan' VA
Ter Arkh; 1990; 62(6):92-4. PubMed ID: 2218937
[TBL] [Abstract][Full Text] [Related]
32. Analysis of cyclosporin A (CsA) concentrations by fluorescence polarization immunoassay (FPIA): comparison with radio immunoassay (RIA) and liquid chromatography (HPLC).
Mraz W; Müller C; Molnar B; Knedel M
Transplant Proc; 1989 Feb; 21(1 Pt 1):885-7. PubMed ID: 2650289
[No Abstract] [Full Text] [Related]
33. Comparison of cyclosporine (CSA) blood levels and RIA/HPLC ratios among renal transplant patients with normal allograft function, CSA nephrotoxicity or rejection.
Veremis SA; Maddux MS; Tang IY; Millner SN; Prasad R; Pollak R; Mozes MF
Transplant Proc; 1989 Feb; 21(1 Pt 2):1476-7. PubMed ID: 2652473
[No Abstract] [Full Text] [Related]
34. Comment to the presentation of clinical correlations with drug measurements.
Land W
Transplant Proc; 1990 Jun; 22(3):1292. PubMed ID: 2349689
[No Abstract] [Full Text] [Related]
35. Monitoring of cyclosporine blood levels with polyclonal and monoclonal assays during episodes of renal graft dysfunction.
Martinez L; Foradori A; Vaccarezza A; Martinez P; Rodriguez L
Transplant Proc; 1989 Feb; 21(1 Pt 2):1490-1. PubMed ID: 2652479
[No Abstract] [Full Text] [Related]
36. Impact of lipoproteins on cyclosporine pharmacokinetics and biological activity in transplant patients.
Awni WM; Heim-Duthoy K; Kasiske BL
Transplant Proc; 1990 Jun; 22(3):1193-6. PubMed ID: 2349681
[No Abstract] [Full Text] [Related]
37. Minimal low dosage of cyclosporine therapy in renal transplantation by careful monitoring of high-performance liquid chromatography whole blood trough levels.
Uchida K; Yamada N; Orihara A; Tominaga Y; Tanaka Y; Hayashi S; Kondo T; Morozumi K; Satake M; Taira N
Transplant Proc; 1988 Apr; 20(2 Suppl 2):394-401. PubMed ID: 3284083
[No Abstract] [Full Text] [Related]
38. Cyclosporine measurement by FPIA, PC-RIA, and HPLC following liver transplantation.
Burckart GJ; Jain A; Diven W; Venkataramanan R; Starzl TE
Transplant Proc; 1990 Jun; 22(3):1319-22. PubMed ID: 2190393
[TBL] [Abstract][Full Text] [Related]
39. [Usefulness of the determination of cyclosporin circulating levels].
Clerico A; Zucchelli GC
Minerva Med; 1992; 83(1-2):1-8. PubMed ID: 1545917
[No Abstract] [Full Text] [Related]
40. Therapeutic cyclosporine monitoring: comparison of radioimmunoassay and high-performance liquid chromatography methods in organ transplant recipients.
Hirvisalo EL; Kivistö KT; Neuvonen PJ
Ther Drug Monit; 1990 Jul; 12(4):353-8. PubMed ID: 2396309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
